Slovenian regulators slam Polydrug API plant in India

By Gareth Macdonald

- Last updated on GMT

Polydrug Labs site in Maharashtra, India
Polydrug Labs site in Maharashtra, India

Related tags European union Beta blocker

Polydrug Laboratories chose not to log customer complaints about APIs made at its plants in Maharashtra according to Slovenian regulators.

The agency for medicinal products and medical devices of the Republic of Slovenia (Jazmp) logged its concerns on the European Union’s Eudra GMP database last night​, explaining that they are based on an inspection conducted on March 18.

The regulators said its inspectors observed 17 breaches of current good manufacturing practices at the facility, five of which it described as ‘major’ including that customer complaints were “deliberately unregistered in the official logbook.”

Other transgressions included that access to quality records is not controlled and that Polydrug failed to “address risks of cross contamination for APIs sent out to micronisation subcontractor​” both of which pose a “potential risk for the patient​.”

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has suspended certificates of suitability (CEP)​ for the seven active pharmaceutical ingredients (APIs) made at the three factories at the Polydrug site.

The affected APIs include the beta blockers metoprolol tartrate and metoprolol succinate, ferrous fumarate and the Pfizer-developed antifungal fluconazole, which is on the World Health Organisation’s (WHO) essential medicines list​.

Mumbai-headquartered Polydrug has yet to comment on the CEP suspension and all of the APIs involved were still listed as available on its website when this article was published.

The firm did not respond to a request for comment ahead of publication.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers